TrialInternational journal of dermatology2026

Secukinumab in the Treatment of Moderate-to-Severe Hidradenitis Suppurativa: Pooled Pharmacokinetics and Safety Results From the SUNSHINE and SUNRISE Phase 3 Studies.

Afsaneh Alavi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.